Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccinationSARS-CoV-2 Lambda 변이체의 단일 클론 항체 및 감염 및 백신 접종에 의해 유도된 중화 항체에 대한 감수성 감소Coronaviruses Published on 2021-12-212022-09-10 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adenovirus Amino acid Analysis antigenicity average C.37 Calu Calu-3 caused Cell cell line cell lines convalescent convalescent sera convalescent serum coronavirus D614G demonstrated distribution Efficacy eight geographic location geographic locations immunized Inactivated vaccine Infection Lambda Lambda variant monoclonal antibodies monoclonal antibody mRNA vaccines multiple mutation multiple mutations Mutation mutations neutralization neutralization ability Neutralizing Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibodies pandemic pseudovirus pseudoviruses R126 Receptor binding domain reduced reduction in reference strain respiratory SARS-CoV-2 sensitivity sera severe acute respiratory syndrome coronavirus 2 South America Spike protein temporal distribution the SARS-CoV-2 the spike protein titre vaccination Vaccine Vaccines variant Viral were used [DOI] 10.1080/22221751.2021.2008775 PMC 바로가기 [Article Type] Coronaviruses
Passive immune therapies: another tool against COVID-19수동 면역 요법: COVID-19에 대한 또 다른 도구Review Published on 2021-12-102022-09-11 Journal: Hematology. American Society of Hematology. Educat [Category] SARS, 진단, 치료제, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval benefit Casirivimab convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Emergency use Evidence fatal COVID-19 Globulin high risk hyperimmune hyperimmune globulin immune immune system Infection Japan lack Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal neutralizing monoclonal antibodies other treatment pandemic Passive Patient patient groups performed Prevent Regulatory required Research respiratory respiratory infections SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe respiratory infections Therapies therapy treat Treatment United Kingdom [DOI] 10.1182/hematology.2021000299 PMC 바로가기 [Article Type] Review
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together밤라니비맙 단독 또는 밤라니비맙과 에테세비맙을 함께 투여받은 경증 또는 중등도 COVID-19 환자에서 SARS-CoV-2에 대한 내인성 항체 반응Clinical Trial Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 임상, 진단, 치료법, 치료제, [키워드] Administered antibodies Antibody Response Antibody titer Antibody titers antigenic B.1.351 bamlanivimab baseline Beta Beta variant binding breadth clinically Cohort collected correlated COVID-19 Day decrease develop domain Effect endogenous epitope Epitopes etesevimab evade Factor full-length Hospitalization humoral immune response in viral investigated longitudinal mAb mAbs Mild Moderate COVID-19 monoclonal antibody monotherapy Mortality multiplex mutant N-terminal domain Neutralization assay Neutralizing activity neutralizing monoclonal antibodies nucleocapsid protein Patient performed Placebo Received receiving recipient reduced reductions in response Result SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 pseudovirus sera serology serum sample specificity subsequent titer titers treated Treatment Trial variant Viral Viral load [DOI] 10.3389/fimmu.2021.790469 PMC 바로가기 [Article Type] Clinical Trial
The biological and clinical significance of emerging SARS-CoV-2 variants신종 SARS-CoV-2 변이체의 생물학적 및 임상적 중요성Review Published on 2021-12-012022-09-11 Journal: Nature reviews. Genetics [Category] Fulltext, SARS, 변종, 유전자 메커니즘, 치료제, [키워드] Alpha variant Beta Beta variant Brazil Clinical research complicate COVID-19 pandemic COVID-19 research delta variant epidemiological Gamma India Laboratory Lineage Mutation neutralizing monoclonal antibodies neutralizing monoclonal antibody pandemic population immunity reduce Reinfection Replication Research rising risk SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants South Africa Spike protein Spread vaccination variant variants of concern virus virus transmission [DOI] 10.1038/s41576-021-00408-x PMC 바로가기 [Article Type] Review
Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG단량체 및 IgG에 비해 SARS-CoV-2 IgA1 이량체의 시험관 내 중화 활성 증가Article Published on 2021-11-022022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antigen antigen binding binding complex coronavirus exhibited expressed expression feature glycosylation homogeneous human proteins IgA IgG IgG1 in vitro Increased monoclonal monoclonal antibodies monomer Neutralizing activity neutralizing monoclonal antibodies neutralizing monoclonal antibody Nicotiana benthamiana plant plant expression plants respiratory SARS-CoV-2 SARS-CoV-2 neutralization severe acute respiratory syndrome Coronavirus significantly increased variant Variation [DOI] 10.1073/pnas.2107148118 PMC 바로가기 [Article Type] Article
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?밤라니비맙이 필요한가요? 에테세비맙이 코로나19 치료의 핵심인가?Article Published on 2021-11-012022-09-11 Journal: Expert opinion on biological therapy [Category] MERS, SARS, 변종, 진단, [키워드] 24 hour 24 hours approach approval Area bamlanivimab benefit Beta BLAZE-1 clinical trial COVID-19 COVID-19 illness critical appraisal death delta variant Effect effective etesevimab expert FDA Hospitalization information Medicine Medicines Mild mild to moderate moderate monoclonal antibodies monoclonal antibody neutralizing monoclonal antibodies not effective occurred pandemic participant Phase 3 phase 3 clinical trial. placebo group Primary outcome producing required risk factor SARS-CoV-2 subject tested the placebo group variant [DOI] 10.1080/14712598.2021.1985458 PMC 바로가기 [Article Type] Article
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High PotencyImmunology Published on 2021-10-262022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] B.1.1.7 B.1.167.2 B.1.351 Beta binding efficiency Blot Cell characterization characterized concern conformational contribute convalescent sera COVID-19 Delta Delta VOC Diagnosis Efficacy epitope epitopes expression Escherichia coli expressed flow cytometry full-length spike protein functional Gamma glycosylated HEK293T cell immunoprecipitation inhibit initial lentivirus mAb mAbs majority mammalian mice immunization monoclonal antibody mouse Mutation NAb neutralization Neutralizing activity neutralizing antibody neutralizing monoclonal antibodies P.1 Pathogenesis plaque-reduction neutralization test potency produced Protein pseudotyped RBD reduction reference sequence response rRBD SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RBD SARS-CoV-2 spike glycoprotein SARS-CoV-2 variant SARS-CoV-2 variants Spike protein suggested supernatant the RBD the SARS-CoV-2 therapy transmembrane Vaccine variants of concern VoC Wuhan [DOI] 10.3389/fimmu.2021.750386 PMC 바로가기 [Article Type] Immunology
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSARS-CoV-2 스파이크 단백질 수용체 결합 도메인에 특이적인 인간 중화 항체의 구조적 기초Research Article Published on 2021-10-132022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 acute respiratory syndrome coronavirus-2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies antibody Antigen assist B cell B.1.1.7 back Basis bind binding caused complex conformation convalescent coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 pandemic crystal structure domain dominant drug drug candidate drug candidates drugs Economy effective Epitopes global health Health Human human Angiotensin-converting enzyme in vivo Intervention Lineage Lineage B.1.1.7 mAbs mechanism monoclonal antibodies monoclonal antibody Mutagenesis mutant NAbs native human monoclonal antibody Neutralizing activity neutralizing antibody neutralizing effect neutralizing epitope neutralizing monoclonal antibodies neutralizing monoclonal antibody New coronavirus not affect Prophylactic prophylactic and therapeutic efficacies RBD RBS-C receptor Receptor-binding domain Research residue respiratory Respiratory disease responsible reveal ridge S-RBD Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Specific spike Spike protein the SARS-CoV-2 the spike protein Therapeutic antibody therapeutic efficacy Transgenic mouse understanding Vaccine Vaccine development variety [DOI] 10.1128/Spectrum.01352-21 PMC 바로가기 [Article Type] Research Article
Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody회복기 혈청 및 VH3-30 단클론항체에 의한 중화에 대한 SARS-CoV-2 변이체의 민감도Immunology Published on 2021-09-232022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antibody Response B.1.1.7 B.1.351 B.1.617.1 binding activity Brazil caused collected convalescent patient Convalescent patients convalescent sera coronavirus coronavirus disease COVID-19 global pandemic India indicated Intervention mAb mAbs Medical countermeasures neutralization neutralizing capacity neutralizing mAb neutralizing monoclonal antibodies neutralizing monoclonal antibody New Novel coronavirus novel coronavirus disease P.1 pandemic respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera severe acute respiratory syndrome Coronavirus South Africa Spread Vaccine variants VH3-30 VoC VOCs wild-type [DOI] 10.3389/fimmu.2021.751584 PMC 바로가기 [Article Type] Immunology
Should the world collaborate imminently to develop neglected live‐attenuated vaccines for COVID‐19?Review Published on 2021-09-212022-10-04 Journal: Journal of medical virology [Category] SARS, 변종, 신약개발, [키워드] accelerate administration clinical trials COVID‐19 COVID‐19 delta variant develop Efficacy Efficiency experiment human vaccine humanized immunologically individual inhibit intramuscular much higher neutralizing monoclonal antibodies pandemic pathogenic virus Policy PROTECT Safe Safety SARS‐CoV‐2 SARS‐CoV‐2 Spread Transmission Vaccine Vaccines variant variants viral disease virus [DOI] 10.1002/jmv.27335 PMC 바로가기 [Article Type] Review